Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Description: Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016

Summary


The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Cervical Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by a team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Cervical Cancer Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Cervical Cancer Diagnostic Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Cervical Cancer Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date

Contents:

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Cervical Cancer Diagnostic Tests Overview
3 Products under Development
3.1 Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development
3.2 Cervical Cancer Diagnostic Tests - Pipeline Products by Territory
3.3 Cervical Cancer Diagnostic Tests - Pipeline Products by Regulatory Path
3.4 Cervical Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date
3.5 Cervical Cancer Diagnostic Tests - Ongoing Clinical Trials
4 Cervical Cancer Diagnostic Tests - Pipeline Products under Development by Companies
4.1 Cervical Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development
4.2 Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development
5 Cervical Cancer Diagnostic Tests Companies and Product Overview
5.1 Abbott Diagnostics Company Overview
5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
5.2 Aindra Systems Pvt. Ltd. Company Overview
5.2.1 Aindra Systems Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview
5.3 Alere Inc. Company Overview
5.3.1 Alere Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.4 Arbor Vita Corporation Company Overview
5.4.1 Arbor Vita Corporation Pipeline Products & Ongoing Clinical Trials Overview
5.5 Becton, Dickinson and Company Company Overview
5.5.1 Becton, Dickinson and Company Pipeline Products & Ongoing Clinical Trials Overview
5.6 BioAffinity Technologies, Inc. Company Overview
5.6.1 BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.7 BioMark Diagnostics Inc. Company Overview
5.7.1 BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.8 BioMark Technologies Inc. Company Overview
5.8.1 BioMark Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.9 Cancer Research Technology Limited Company Overview
5.9.1 Cancer Research Technology Limited Pipeline Products & Ongoing Clinical Trials Overview
5.10 Cepheid Company Overview
5.10.1 Cepheid Pipeline Products & Ongoing Clinical Trials Overview
5.11 China Sky One Medical, Inc. Company Overview
5.11.1 China Sky One Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
5.12 Cytosystems Ltd Company Overview
5.12.1 Cytosystems Ltd Pipeline Products & Ongoing Clinical Trials Overview

5.13 Enzo Life Sciences, Inc. Company Overview

5.13.1 Enzo Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview

5.14 Genisphere Inc. Company Overview

5.14.1 Genisphere Inc. Pipeline Products & Ongoing Clinical Trials Overview

5.15 Genomic Vision Company Overview

5.15.1 Genomic Vision Pipeline Products & Ongoing Clinical Trials Overview

5.16 GenomicTree, Inc. Company Overview

5.16.1 GenomicTree, Inc. Pipeline Products & Ongoing Clinical Trials Overview

5.17 Golden Valley Development, Inc. Company Overview

5.17.1 Golden Valley Development, Inc. Pipeline Products & Ongoing Clinical Trials Overview

5.18 GRANT Life Sciences, Inc. Company Overview

5.18.1 GRANT Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview

5.19 Louisville Bioscience, Inc. Company Overview

5.19.1 Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview

5.20 MDNA Life Sciences, Inc. Company Overview

5.20.1 MDNA Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview

5.21 MDxHealth SA Company Overview

5.21.1 MDxHealth SA Pipeline Products & Ongoing Clinical Trials Overview

5.22 Milagen, Inc. Company Overview

5.22.1 Milagen, Inc. Pipeline Products & Ongoing Clinical Trials Overview

5.23 NeoDiagnostix, Inc. Company Overview

5.23.1 NeoDiagnostix, Inc. Pipeline Products & Ongoing Clinical Trials Overview

5.24 Newcastle University Company Overview

5.24.1 Newcastle University Pipeline Products & Ongoing Clinical Trials Overview

5.25 Oncgnostics GmbH Company Overview

5.25.1 Oncgnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview

5.26 ONCOVEDA Cancer Research Center Company Overview

5.26.1 ONCOVEDA Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview

5.27 Orion Genomics LLC Company Overview

5.27.1 Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview

5.28 Precision Biologics, Inc. Company Overview
5.28.1 Precision Biologics, Inc. Pipeline Products & Ongoing Clinical Trials Overview

5.29 Preciva Incorporated Company Overview

5.29.1 Preciva Incorporated Pipeline Products & Ongoing Clinical Trials Overview

5.30 Roche Diagnostics International Ltd. Company Overview

5.30.1 Roche Diagnostics International Ltd. Pipeline Products & Ongoing Clinical Trials Overview

5.31 University of Manchester Company Overview

5.31.1 University of Manchester Pipeline Products & Ongoing Clinical Trials Overview

5.32 US Biomarkers, Inc. Company Overview

5.32.1 US Biomarkers, Inc. Pipeline Products & Ongoing Clinical Trials Overview

5.33 Vanderbilt University Company Overview

5.33.1 Vanderbilt University Pipeline Products & Ongoing Clinical Trials Overview

5.34 Vigilant Biosciences, Inc. Company Overview

5.34.1 Vigilant Biosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview

5.35 XEPTAGEN SpA Company Overview

5.35.1 XEPTAGEN SpA Pipeline Products & Ongoing Clinical Trials Overview

6 Cervical Cancer Diagnostic Tests - Recent Developments

6.1 Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter

6.2 Jul 28, 2016: BD Names R. Andrew Eckert To Board Of Directors

6.3 Jul 28, 2016: Cepheid Reports Second Quarter 2016 Results

6.4 Jul 26, 2016: Genomic Vision Announces Results For The First Half Of 2016

6.5 Jul 21, 2016: Quest Diagnostics Reports Second Quarter 2016 Financial Results

6.6 Jul 20, 2016: Genomic Vision is accelerating its clinical trial in cervical cancer with an additional study in the Czech Republic

6.7 Jul 11, 2016: Vigilant Biosciences Raises USD5 Million in Series B2 Financing Round

6.8 Jul 07, 2016: bioAffinity Technologies Appoints New Senior VP for Research & Development of Therapeutics

6.9 Jun 27, 2016: Cancer Genetics Names Healthcare Technology Industry Veteran John Jay Roberts as COO and Executive Vice President of Finance

6.10 Jun 16, 2016: The Clinical Trial Undertaken by Genomic Vision and Reims University Hospital to Validate a New Test for the Early Detection and Treatment of Cervical Cancer Was Chosen for an Oral Presentation at the Eurogin Congress in Salzburg

6.11 Jun 15, 2016: Qiagen Enters into Licensing Agreement with MDxHealth

6.12 Jun 15, 2016: Quest Diagnostics and Safeway Team to Offer Convenient Diagnostic Testing to Customers in More States
6.13 May 31, 2016: Quest Diagnostics and HCA's HealthONE System Partner to Deliver High-Value and Innovative Laboratory Services at Six Denver-Area HealthONE Hospitals

6.14 May 25, 2016: MEDITE Cancer Diagnostics Raises USD0.15 Million in Venture Financing

6.15 May 25, 2016: Stage I Diagnostics Raises USD0.1 Million in Venture Financing

6.16 May 25, 2016: Vigilant Biosciences Names Scientific Advisory Board and Expands Leadership Team, Appoints Dr. Michael Donovan as Chief Clinical Officer

6.17 May 23, 2016: Quest Diagnostics Raises USD500 Million in Public Offering of 3.45% Senior Notes due 2026

6.18 May 17, 2016: Cancer Prevention and Research Institute of Texas Marks Progress at the Halfway Point of its Funding

6.19 May 10, 2016: Cancer Genetics Announces 39% Revenue Increase and Provides Recent Company Highlights

6.20 Mar 08, 2016: Roche receives China Food and Drug Administration approval for the CINtec PLUS Cytology test to help prevent women from developing cervical cancer

6.21 Jan 20, 2016: Safe Diagnostics for Women Tested HPV-Positive


6.23 Sep 18, 2015: Fast and Reliable Results in Cancer Diagnostics: Biotech Startup Oncgnostics Receives CE Mark for Cervical Cancer Test GynTect

6.24 Sep 17, 2015: Cancer Genetics to Report Results From Two Independent Studies at the 30th International Papillomavirus Conference & Clinical and Public Health Workshops (HPV 2015)

7 Appendix

7.1 Methodology

7.2 About

7.3 Contact Us

7.4 Disclaimer

1.1 List of Tables

Table 1: Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development

Table 2: Cervical Cancer Diagnostic Tests - Pipeline Products by Territory

Table 3: Cervical Cancer Diagnostic Tests - Pipeline Products by Regulatory Path

Table 4: Cervical Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date

Table 5: Cervical Cancer Diagnostic Tests - Ongoing Clinical Trials

Table 6: Cervical Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development

Table 7: Cervical Cancer Diagnostic Tests - Pipeline Products by Stage of Development

Table 8: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview

Table 9: TERC Companion Diagnostic Assay - Cervical Cancer - Product Status
Table 10: TERC Companion Diagnostic Assay - Cervical Cancer - Product Description
Table 11: Aindra Systems Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 12: Aindra Device - Product Status
Table 13: Aindra Device - Product Description
Table 14: Alere Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 15: NMP179 Test - Product Status
Table 16: NMP179 Test - Product Description
Table 17: Arbor Vita Corporation Pipeline Products & Ongoing Clinical Trials Overview
Table 18: AVantage HPV E6 Test - Product Status
Table 19: AVantage HPV E6 Test - Product Description
Table 20: Becton, Dickinson and Company Pipeline Products & Ongoing Clinical Trials Overview
Table 21: BD SurePath Plus Molecular Pap Test System - Product Status
Table 22: BD SurePath Plus Molecular Pap Test System - Product Description
Table 23: Biomarker-Cervical Cancer - Product Status
Table 24: Biomarker-Cervical Cancer - Product Description
Table 25: BioAffinity Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 26: CyPath Diagnostic Assay - Cervical Cancer - Product Status
Table 27: CyPath Diagnostic Assay - Cervical Cancer - Product Description
Table 28: BioMark Diagnostics Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 29: Metabolomics-based Diagnostic Assay - Cervical Cancer - Product Status
Table 30: Metabolomics-based Diagnostic Assay - Cervical Cancer - Product Description
Table 31: BioMark Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Biomarker Assay - Cervical Cancer - Product Status
Table 33: Biomarker Assay - Cervical Cancer - Product Description
Table 34: Cancer Research Technology Limited Pipeline Products & Ongoing Clinical Trials Overview
Table 35: MCM Test - Cervical Cancer - Product Status
Table 36: MCM Test - Cervical Cancer - Product Description
Table 37: Cepheid Pipeline Products & Ongoing Clinical Trials Overview
Table 38: Xpert Molecular PAP Assay - Product Status
Table 39: Xpert Molecular PAP Assay - Product Description
Table 40: China Sky One Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 41: Diagnostic Kit - Carcinoma Cervix - Product Status
Table 42: Diagnostic Kit - Carcinoma Cervix - Product Description
Table 43: Cytosystems Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 44: Laboratory-Based Diagnostic Test - Cervical Cancer - Product Status
Table 45: Laboratory-Based Diagnostic Test - Cervical Cancer - Product Description
Table 46: Enzo Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 47: Next-Generation Branched DNA Assay - Cervical Cancer - Product Status
Table 48: Next-Generation Branched DNA Assay - Cervical Cancer - Product Description
Table 49: Genisphere Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 50: miRNA Biomarker Diagnostic Test - Cervical Cancer - Product Status
Table 51: miRNA Biomarker Diagnostic Test - Cervical Cancer - Product Description
Table 52: Genomic Vision Pipeline Products & Ongoing Clinical Trials Overview
Table 53: HPV Combing Test - Product Status
Table 54: HPV Combing Test - Product Description
Table 55: Genomic Vision - Ongoing Clinical Trials Overview
Table 56: HPV Combing Test - Integration of Oncogenic HPV DNA
Table 57: HPV Combing Test - Integration of Oncogenic HPV DNA in Czech Republic
Table 58: GenomicTree, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 59: EarlyTect Cervical Cancer - Product Status
Table 60: EarlyTect Cervical Cancer - Product Description
Table 61: Screening Test - Cervical Cancer - Product Status
Table 62: Screening Test - Cervical Cancer - Product Description
Table 63: Golden Valley Development, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 64: XytoTest - Product Status
Table 65: XytoTest - Product Description
Table 66: GRANT Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 67: Serum-Based Test - Cervical Cancer - Product Status
Table 68: Serum-Based Test - Cervical Cancer - Product Description
Table 69: Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 70: Cervical Cancer Remission pT Test - Product Status
Table 71: Cervical Cancer Remission pT Test - Product Description
Table 72: MDNA Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 73: Diagnostic Test - Cervical Cancer - Product Status
Table 74: Diagnostic Test - Cervical Cancer - Product Description
Table 75: MDxHealth SA Pipeline Products & Ongoing Clinical Trials Overview
Table 76: ClinicalMDx - Cervical Cancer - Product Status
Table 77: ClinicalMDx - Cervical Cancer - Product Description
Table 78: Milagen, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 79: Immunoassay - Cervical Cancer - Product Status
Table 80: Immunoassay - Cervical Cancer - Product Description
Table 81: NeoDiagnostix, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 82: Cervical DNA Dtex Test - Product Status
Table 83: Cervical DNA Dtex Test - Product Description
Table 84: Newcastle University Pipeline Products & Ongoing Clinical Trials Overview
Table 85: SmartHEALTH POC System - Cervical Cancer - Product Status
Table 86: SmartHEALTH POC System - Cervical Cancer - Product Description
Table 87: Oncgnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 88: GynTect - Product Status
Table 89: GynTect - Product Description
Table 90: ONCOVEDA Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview
Table 91: HPV Companion Diagnostic Test - Cervical Cancer - Product Status
Table 92: HPV Companion Diagnostic Test - Cervical Cancer - Product Description
Table 93: Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 94: Diagnostic Assay - Cervical Cancer - Product Status
Table 95: Diagnostic Assay - Cervical Cancer - Product Description
Table 96: Precision Biologics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 97: Diagnostic Assay - Cervical Cancer - Product Status
Table 98: Diagnostic Assay - Cervical Cancer - Product Description
Table 99: Preciva Incorporated Pipeline Products & Ongoing Clinical Trials Overview
Table 100: mColposcope - Product Status
Table 101: mColposcope - Product Description
Table 102: Roche Diagnostics International Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 103: CINtec Plus Cytology Kit - Product Status
Table 104: CINtec Plus Cytology Kit - Product Description
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3806083/">http://www.researchandmarkets.com/reports/3806083/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCH3G8PJ</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 8000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 12000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr □</th>
<th>Mrs □</th>
<th>Dr □</th>
<th>Miss □</th>
<th>Ms □</th>
<th>Prof □</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World